<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Platinum Priority -Prostate Cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Kurt</forename><surname>Miller</surname></persName>
							<email>kurt.miller@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joan</forename><surname>Carles</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Valld&apos;Hebron Institute of Oncology</orgName>
								<orgName type="institution" key="instit2">Valld&apos;Hebron University Hospital</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ju</forename><surname>¨rgen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Gschwend</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Technical University of Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hendrik</forename><surname>Van Poppel</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">Katholieke Universiteit Leuven</orgName>
								<address>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joris</forename><surname>Diels</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Janssen EMEA HEMAR</orgName>
								<address>
									<settlement>Beerse</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sabine</forename><forename type="middle">D</forename><surname>Brookman-May</surname></persName>
							<email>sabine.brookman-may@email.de</email>
							<affiliation key="aff5">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Ludwig-Maximilians University (LMU) Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">Janssen Research &amp; Development</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">_</forename><surname>T D $ D I F F ]</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Giacomo</forename><surname>Novara</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Brookman-May</forename><surname>Diels</surname></persName>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">$ D I F F ] ** Corresponding author. Department of Urology</orgName>
								<orgName type="institution">Ludwig-Maximilians University (LMU) Munich</orgName>
								<address>
									<addrLine>Marchioninistrasse 15</addrLine>
									<postCode>D-81377</postCode>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Department of Urology</orgName>
								<address>
									<addrLine>Charite ´Berlin, Charite ´platz 1</addrLine>
									<postCode>D-10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">Brookman-May</orgName>
								<address>
									<settlement>Miller, Carles, Gschwend</settlement>
									<region>Van Poppel</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<address>
									<addrLine>3 _ T D $ D I F F ]</addrLine>
									<settlement>Brookman-May</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Platinum Priority -Prostate Cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">748E178D464EEBB94EFAC2911FE3EC8C</idno>
					<idno type="DOI">10.1016/j.eururo.2017.08.035</idno>
					<note type="submission">Accepted August 29, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:14+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Abiraterone acetate Metastatic castration-resistant prostate cancer Stratification Prognostic discrimination Predictive parameters Diels</term>
					<term>Brookman-May Miller</term>
					<term>Carles</term>
					<term>Gschwend</term>
					<term>Van Poppel</term>
					<term>Diels</term>
					<term>Brookman-May Administrative</term>
					<term>technical</term>
					<term>or material support: None</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: In the COU-AA-302 study (NCT00887198), abiraterone acetate plus prednisone (AAP) significantly improved outcomes in patients with metastatic castrationresistant prostate cancer (mCRPC) versus prednisone alone.</s><s>Baseline clinical parameters predicting that treatment response could help inform clinical decisions were explored.</s><s>Objective: To identify patients who derive the greatest clinical benefit from AAP treatment.</s><s>Design, setting, and participants: A total of 1088 mCRPC patients treated with either AAP or prednisone in the first-line setting in COU-AA-302 were included in this post hoc analysis.</s><s>Intervention: Abiraterone acetate1000 mg daily versus placebo, both plus prednisone 10 mg daily.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Outcome measurements and statistical analysis: Univariate and multivariable Cox regression analyses were performed, including clinical and pathological parameters for the primary end points overall survival (OS) and radiographic progression-free survival (rPFS), and secondary study end points.</s><s>Tumor-associated baseline parameters independently impacting OS were applied to stratify patients according to possible treatment effects.</s><s>Results and limitations: Baseline prostate-specific antigen (PSA), tumor-related pain as assessed by the Brief Pain Inventory-Short Form (BPI-SF), and Gleason score (GS) at primary diagnosis were identified as tumor-associated variables that independently impacted OS.</s><s>AAP significantly improved outcomes versus prednisone in both group 1 (BPI-SF 0-1 and PSA &lt;80 ng/ml and GS &lt;8; p = 0.006; hazard ratio [HR]: 0.61) and group 2 (BPI-SF 2-3 and/ or PSA 80 ng/ml and/or GS 8; p = 0.03; HR: 0.84).</s><s>The differences observed for treatment effects between groups 1 and 2 for OS (HR: 0.61 vs 0.84), rPFS (HR: 0.41 vs 0.59), and time to chemotherapy (HR: 0.64 vs 0.71) were not statistically significant.</s></p><p><s>1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>The therapeutic landscape in metastatic castration-resistant prostate cancer (mCRPC) has expanded in recent years with the introduction of several novel anticancer drugs prolonging overall survival (OS), including the CYP17 inhibitor abiraterone acetate (AA), the androgen-receptor antagonist enzalutamide, the radioisotope alpharadin (radium-223), the taxane cabazitaxel, and the vaccine sipuleucel-T (marketing authorization withdrawn in the European Union) <ref type="bibr" target="#b4">[1]</ref><ref type="bibr" target="#b5">[2]</ref><ref type="bibr" target="#b6">[3]</ref>.</s><s>These treatment options exploit different mechanisms of action; therefore, different biomarkers and prognostic variables are most relevant to measuring and predicting treatment response for different agents.</s></p><p><s>Independent predictors of OS previously identified include, but are not limited to, tumor-associated markers such as prostate-specific antigen (PSA) and Gleason score (GS), bone turnover markers such as alkaline phosphatase (ALP), patient-related factors such as cancer-related pain and performance status, metastatic distribution (eg, presence or absence of visceral metastases), and laboratory parameters, including hemoglobin, lactate dehydrogenase (LDH), albumin, and neutrophil-to-lymphocyte ratio <ref type="bibr" target="#b4">[1,</ref><ref type="bibr" target="#b7">4]</ref>.</s><s>Further research into predictors of patient response to different treatments would benefit physicians, supporting evidence-based clinical decision making on initial treatment selection and optimal sequential treatments <ref type="bibr" target="#b4">[1]</ref>.</s></p><p><s>AA in combination with prednisone (AAP) was initially approved in 2011 for the treatment of mCRPC patients after chemotherapy, and subsequently for the first-line treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients based on results from the pivotal phase 3 COU-AA-302 study (NCT00887198) <ref type="bibr" target="#b8">[5,</ref><ref type="bibr" target="#b9">6]</ref>.</s><s>In COU-AA-302, AAP significantly improved median radiographic progression-free survival (rPFS) and median OS versus placebo plus prednisone (PP) <ref type="bibr" target="#b9">[6]</ref>, and delayed clinical deterioration and initiation of chemotherapy <ref type="bibr" target="#b8">[5]</ref>.</s><s>Similar survival benefit from AAP was observed across several predefined patient subgroups, regardless of baseline Eastern Cooperative Oncology Group performance status(ECOG PS) (0 vs 1), tumor-associated pain assessed by the Brief Pain Inventory-Short Form (BPI-SF) score (0-1 vs 2-3), metastatic sites (bone only or bone and other sites), age (&lt;65, 65, or 75 yr), and PSA, LDH, and ALP levels <ref type="bibr" target="#b8">[5,</ref><ref type="bibr" target="#b9">6]</ref>.</s></p><p><s>More in-depth analysis of outcomes across patient subgroups may reveal differential treatment effects and point to clinical characteristics with prognostic value in predicting treatment response.</s><s>Here, we report a post hoc analysis of COU-AA-302 with patients stratified according to baseline characteristics, with the aims of identifying patients deriving the greatest clinical benefit from AAP treatment and describing prostate cancer-related parameters identified at initiation of therapy to inform further clinical decisions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.</head><p><s>Patients and methods COU-AA-302 was a phase 3, double-blind, placebo-controlled, randomized clinical trial in which 1088 asymptomatic or mildly symptomatic chemotherapy-naïve mCRPC patients received prednisone 5 mg twice daily plus AA 1000 mg once daily or placebo (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Details of the study design have been reported previously <ref type="bibr" target="#b8">[5]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>[ ( F i g . _ 1 ) T D $ F I G ]</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Univariate and multivariable analyses of OS</head><p><s>Univariate analysis identified several variables with a significant association with OS (Table <ref type="table" target="#tab_1">1</ref>).</s><s>Significance was maintained on multivariable analysis for baseline BPI-SF score, PSA, hemoglobin, LDH, ALP, age, and GS at primary diagnosis (Table <ref type="table" target="#tab_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.1.">Stratified analysis</head><p><s>Of those parameters with a significant impact on OS on multivariable analysis, parameters directly associated with prostate cancer (ie, tumor-related pain/BPI-SF, PSA, and GS) were selected for additional evaluation of potential predictive relevance for the treatment efficacy of AAP.</s></p><p><s>Other parameters, including LDH, ALP, and hemoglobin, had an independent impact on OS; however, as these are not prostate cancer-specific markers with the potential to change for reasons other than tumor progression, they were not considered for additional evaluation and stratification.</s><s>Pain, PSA, and GS were used to stratify patients into two groups: group 1 patients were asymptomatic, reporting no tumor-related pain (BPI-SF 0-1), PSA &lt;80 ng/ml, and GS &lt;8; group 2 patients had mild pain (BPI-SF 2) and/or PSA 80 ng/ml and/or GS 8.</s><s>The BPI-SF cut-off allowed patients to be categorized into those with no and mild pain; the GS cutoff categorizes patients with poorly differentiated versus  well or moderately differentiated tumors.</s><s>The cutoff of 80 ng/ml for PSA was selected due to the largest differentiation of HR for OS between groups.</s><s>In total, 824 patients met the criteria for group 2, based on higher levels/scores in at least one of the three stratification parameters, while approximately one-quarter were asymptomatic and had lower PSA levels and GS (group 1; n = 264).</s><s>Patients in groups 1 and 2 were evenly distributed across treatment arms: in the AAP arm (n = 546), 23% (n = 124) and 77% (n = 422) of patients were in groups 1 and 2, respectively; in the PP arm (n = 542), the proportions were 26% (n = 140) and 74% (n = 402), respectively.</s><s>Baseline characteristics for both groups are shown in Table <ref type="table">2</ref>.</s></p><p><s>In both groups, treatment with AAP significantly prolonged median OS, rPFS, time to chemotherapy use, time to opiate use, and treatment duration versus PP (Fig. <ref type="figure" target="#fig_3">2</ref> and Table <ref type="table" target="#tab_2">3</ref>).</s><s>The median OS was 53.</s><s>interaction effects based on subgroup stratification by PSA, pain, and GS were not significantly different (group 1: p = 0.12; group 2: p = 0.74).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>This post hoc analysis of the COU-AA-302 study revealed that both patient groups achieved significantly improved outcomes with AAP versus PP, including improvements in OS and rPFS as well as in secondary study end points, regardless of pain and PSA levels at study entry and GS at primary diagnosis.</s><s>While OS, rPFS, and time to chemotherapy and opiate use were longer in asymptomatic mCRPC patients, defined as patients with lacking or very minimal prostate cancer-related pain, PSA levels &lt;80 ng/ml at the start of treatment and a GS of &lt;8 at primary diagnosis compared with patients with higher PSA levels, pain at the start of treatment, or a higher GS at primary diagnosis, no statistically significant different treatment interactions could be confirmed between both groups.</s><s>A prognostic index model developed in a previous analysis of data from COU-AA-302 identified the presence of more bone metastases (10 vs &lt;10), LDH or ALP levels above the upper limit of normal, and a higher BPI-SF score (2-3 vs 0-1) as risk factors for worse prognosis in this patient population <ref type="bibr" target="#b11">[8]</ref>.</s><s>The current study results were consistent with this prognostic index model in identifying LDH, ALP, and tumor-related pain as having a significant association with OS, as well as PSA, GS, hemoglobin, and age.</s><s>Since parameters such as LDH, ALP, and hemoglobin are nonspecific and could change for reasons besides tumor progression, we focused on tumor-related parameters to stratify patients and identify predictors of treatment response.</s><s>This post hoc analysis was also consistent with previous analyses of predefined subgroups <ref type="bibr" target="#b8">[5,</ref><ref type="bibr" target="#b9">6]</ref> showing that that AAP was effective across the spectrum of patients participating in this trial.</s></p><p><s>While patients with lower levels of PSA and tumorrelated pain at the start of treatment and a lower GS at primary diagnosis had enhanced OS, rPFS, and secondary end points in comparison with those with higher PSA or pain levels or a higher GS, no significant difference was finally found in treatment effects between both patient groups.</s><s>Hence, based on the results of this study, conclusions concerning treatment decision making and timing of treatment initiation in routine clinical practice cannot be drawn.</s><s>Nonetheless, potential benefits by initiation of first-line treatment at a time point when pain and PSA elevation are limited to both delay the requirement for chemotherapy and improve survival outcomes are supported by the results of further studies and analyses.</s><s>For example, in the PREVAIL study investigating enzalutamide in patients with chemotherapy-naïve mCRPC, patients in the placebo arm had rapid progression with a median 2.8 mo to PSA progression only <ref type="bibr" target="#b13">[9]</ref>.</s></p><p><s>The stratification parameters identified in the present analysis may have varying degrees of value in determining patient prognoses.</s><s>Cancer-related pain has been reported to be prognostic in mCRPC, independent of treatment, and may indicate the presence of more advanced disease <ref type="bibr" target="#b14">[10,</ref><ref type="bibr" target="#b15">11]</ref>.</s><s>There is also evidence that patient-reported parameters such as cancer pain might be more reliable than laboratory parameters for outcome prediction <ref type="bibr" target="#b16">[12,</ref><ref type="bibr" target="#b17">13]</ref>.</s><s>PSA elevation has been shown in some studies to be associated with worse outcomes when considered as an independent prognostic marker <ref type="bibr" target="#b7">[4,</ref><ref type="bibr" target="#b14">10,</ref><ref type="bibr" target="#b18">14]</ref>.</s><s>As a predictive indicator of treatment response, lower baseline PSA was associated with better survival outcomes in trials of sipuleucel-T <ref type="bibr" target="#b19">[15]</ref> and AAP <ref type="bibr" target="#b20">[16]</ref>, but not enzalutamide <ref type="bibr" target="#b22">[17]</ref>.</s><s>In a post hoc analysis of the COU-AA-302 study in which patients were stratified into quartiles according to baseline PSA, radiographic progression and mortality risk decreased with decreasing baseline PSA, and the relative benefit of AAP versus PP was greatest in patients with lower baseline PSA <ref type="bibr" target="#b20">[16]</ref>.</s><s>Low baseline PSA also predicted longterm treatment response to AAP as second-line treatment after prior docetaxel treatment <ref type="bibr" target="#b23">[18]</ref>.</s><s>Similarly, patients in the lowest quartile for baseline PSA derived greatest benefit from sipuleucel-T treatment in the IMPACT study <ref type="bibr" target="#b19">[15]</ref>.</s><s>Accordingly, in a previous interim analysis of the COU-AA-302 trial, it has been shown that patients with low PSA values and no tumor-related pain had a significantly better clinical treatment effect than patients with advanced PSA and pain levels <ref type="bibr">[19]</ref>.</s><s>In contrast, in the AFFIRM study evaluating the efficacy of enzalutamide following docetaxel treatment, analysis by baseline PSA quartile found that the treatment effect on OS was consistent regardless of baseline PSA levels <ref type="bibr" target="#b22">[17]</ref>.</s><s>In mCRPC patients receiving enzalutamide as first-line treatment in the PREVAIL study, subgroup analyses showed no difference in survival outcomes for those with baseline PSA above versus below the median <ref type="bibr" target="#b13">[9]</ref>.</s></p><p><s>PSA kinetics (eg, rate of doubling from baseline) <ref type="bibr" target="#b24">[20]</ref> and change in PSA during the first few months of treatment <ref type="bibr" target="#b25">[21]</ref> may also be useful indicators of response to AAP; monitoring these parameters following initiation of treatment may help guide decisions on whether, or at which point, switching to the next treatment is indicated.</s><s>PSA subforms (free PSA and pro-PSA, in addition to total PSA) may also be useful indicators of early response to AAP <ref type="bibr" target="#b26">[22]</ref>.</s></p><p><s>GS may have reduced prognostic significance in mCRPC compared with earlier disease, although a higher GS, which might increase during the natural history of the disease, has been associated with shorter OS <ref type="bibr" target="#b4">[1,</ref><ref type="bibr" target="#b27">23]</ref>.</s><s>There are, however, several considerations when analyzing the predictive or prognostic value of GS in clinical trials and routine clinical practice in mCRPC patients.</s><s>GS is regularly based on biopsy taken at initial diagnosis or tissue from radical prostatectomy; this may have been several years prior to study entry, during which time histological changes, including development to a higher GS, may have occurred such that the GS does not reflect the true histology at the time of study treatment initiation.</s><s>Furthermore, it is well known that there is a lack of concordance between biopsy GS and definitive GS in tissue obtained in radical prostatectomy <ref type="bibr" target="#b28">[24]</ref>.</s><s>In the COU-AA-302 study, half of the samples were from biopsy and half from prostatectomy specimens.</s><s>Furthermore, the grading system for GS was amended in 2005; therefore, samples taken before 2005 (which applies for some patients in the COU-AA-302 study) may be scored differently from those taken more recently and graded according to the International Society of Urological Pathology modified Gleason grading system <ref type="bibr" target="#b30">[25]</ref>.</s><s>Considerable inter-and intraobserver variation in the assessment of GS has also been noted <ref type="bibr" target="#b31">[26]</ref>.</s><s>In a previously published analysis, GS alone (&lt;8 vs 8) also did not significantly predict benefit from AAP versus PP <ref type="bibr" target="#b32">[27]</ref>.</s><s>In light of these analyses and considerations, the use of initial diagnostic GS for clinical decision making in mCRPC patients implies relevant limitations and, hence, should not be a key consideration when deciding whether to treat with AAP or not.</s></p><p><s>The present study is not devoid of limitations, including its post hoc nature.</s><s>However, it was performed in a prospective randomized clinical trial patient cohort, applying predefined baseline and stratification factors for additional analysis.</s><s>As we could not confirm significantly different treatment effects based on baseline characteristics, further research is required to establish whether mCRPC patients benefit from early initiation of AAP or other compounds at a disease stage where they are asymptomatic and have low PSA levels, and to determine roles of different systemic treatment options in mCRPC patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions</head><p><s>This post hoc analysis of the COU-AA-302 study revealed that all patients regardless of baseline characteristics achieved significantly improved outcomes with AAP versus PP.</s><s>OS, rPFS, and time to chemotherapy and opiate use were longer in asymptomatic mCRPC patients with PSA levels &lt;80 ng/ml at the start of treatment and a GS of &lt;8 at primary diagnosis compared with patients with advanced PSA or pain levels or a GS of 8. Since there was no significantly different treatment effect between both groups, conclusions for clinical decision making cannot be drawn yet.</s><s>External validation in CRPC patient cohorts is required to establish a potential clinical benefit of early treatment initiation and determine roles of different treatment options in mCRPC patients.</s><s>These results have been published in part at the European Urology Association Congress, Munich, Germany, 11-15 March 2016; abstract 775.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 -</head><label>1</label><figDesc><div><p><s>Fig. 1 -CONSORT study flow diagram.</s><s>CONSORT = Consolidated Standards of Reporting Trials; ITT = intention to treat.</s></p></div></figDesc><graphic coords="2,315.84,511.14,216.00,209.08" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Table 2 - 2 Characteristic</head><label>22</label><figDesc><div><p><s>phosphatase; BPI-SF = Brief Pain Inventory-Short Form; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; Hb = hemoglobin; HR = hazard ratio; LDH = lactate dehydrogenase; PSA = prostate-specific antigen.</s><s>Baseline characteristics of patients in the overall study population and in groups 1 and ALP, IU/l (IQR) 91 (IQR: 69-136) 79 (IQR: 64-102) 97 (IQR: 72-151) Median age, yr 70 (IQR: 64-77) 70 (IQR: 64-76.5)</s><s>71 (IQR: 64-77) ALP = alkaline phosphatase; BPI-SF = Brief Pain Inventory-Short Form; ECOG PS = Eastern Cooperative Oncology Group performance status; Hb = hemoglobin; IQR = interquartile range; LDH = lactate dehydrogenase; PSA = prostate-specific antigen.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>6 versus 41.8 mo (HR: 0.61; 95% confidence interval [CI], 0.43-0.87;</s><s>p = 0.006) in group 1 compared with 31.2 versus 28.4 mo (HR: 0.84; 95% CI, 0.72-0.99;</s><s>p = 0.03) in group 2. Respective results for rPFS were 27.6 versus 11.1 mo (HR: 0.41; 95% CI, 0.30-0.57;</s><s>p &lt; 0.001) compared with 13.7 versus 8.2 mo (HR: 0.59; 95% CI, 0.50-0.70;</s><s>p &lt; 0.001).</s><s>Median time to chemotherapy was 37.0 versus 24.3 mo (HR: 0.64; 95% CI, 0.46-0.89;</s><s>p = 0.007) in group 1 compared with 23.3 versus 14.5 mo (HR: 0.71; 95% CI, 0.60-0.85;</s><s>p &lt; 0.001) in group 2. The [ ( F i g .</s><s>_ 2 ) T D $ F I G ]</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 2 -</head><label>2</label><figDesc><div><p><s>Fig. 2 -Kaplan-Meier analysis of time-to-event end points with abiraterone acetate plus prednisone and prednisone: (A) overall survival; (B) radiographic progression-free survival.</s><s>(C) time to chemotherapy; and (D) time to opiate use.</s><s>AA = abiraterone acetate; P = prednisone.</s></p></div></figDesc><graphic coords="4,55.33,62.93,479.95,478.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>AAP = abiraterone acetate + prednisone; CI = confidence interval; HR = hazard ratio; NR = not reached; PP = placebo + prednisone; PFS = progression-free survival.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>up was 49.2 mo. As a first step, baseline demographic, clinical, and laboratory parameters were analyzed for association with OS in the overall study population using univariate and multivariable Cox Conclusions</head><label></label><figDesc><div><p><s>: AAP significantly improved outcomes in mCRPC patients compared with prednisone alone regardless of baseline pain and PSA level, and GS at primary diagnosis with no significant differences between observed treatment effects in groups 1 and 2. Patient summary: Treatment with abiraterone acetate and prednisone (compared with treatment with prednisone only) for metastatic castration-resistant prostate cancer increased survival in all patients in the study regardless of pain, prostate-specific antigen levels at the start of treatment, and Gleason score at primary diagnosis.©</s><s>2017 European Association of Urology.</s><s>Published by Elsevier B.V. All rights reserved.</s></p></div></figDesc><table><row><cell>Patients had mCRPC after PSA</cell></row><row><cell>progression according to Prostate Cancer Clinical Trials Working Group</cell></row><row><cell>2 criteria [7] or radiographic progression under ongoing androgen-</cell></row><row><cell>deprivation therapy, serum testosterone levels &lt;50 ng/dl, ECOG PS grade</cell></row><row><cell>0 or 1, no or mild tumor-related pain (BPI-SF scores of 0-1</cell></row><row><cell>[asymptomatic] or 2-3 [mildly symptomatic]), and hematological and</cell></row><row><cell>chemical laboratory values that met predefined criteria. Patients with</cell></row><row><cell>visceral metastases or those who had received previous ketoconazole</cell></row><row><cell>therapy lasting &gt;7 d were excluded.</cell></row></table><note><p><s>This stratification analysis utilized the final dataset from the COU-AA-302 study.</s><s>Median follow-up duration for patients alive at the end of follow-</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 -</head><label>1</label><figDesc><div><p><s>Univariate and multivariable Cox regression analysis for the end point overall survival</s></p></div></figDesc><table><row><cell>Univariate analysis</cell><cell></cell><cell>Multivariable analysis</cell><cell></cell></row><row><cell>HR (95% CI)</cell><cell>p value</cell><cell>HR (95% CI)</cell><cell>p value</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 -</head><label>3</label><figDesc><div><p><s>Analysis of time-to-event end points with abiraterone acetate plus prednisone and prednisone plus placebo within groups 1 and 2</s></p></div></figDesc><table><row><cell></cell><cell>Group 1</cell><cell></cell><cell>Group 2</cell><cell></cell></row><row><cell></cell><cell>AAP (n = 124)</cell><cell>PP (n = 140)</cell><cell>AAP (n = 422)</cell><cell>PP (n = 402)</cell></row><row><cell>Overall survival</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median, mo (IQR)</cell><cell>53.6 (33.7-NR)</cell><cell>41.8 (23.4-53.6)</cell><cell>31.2 (19.4-50.4)</cell><cell>28.4 (17.9-41.9)</cell></row><row><cell>Number of events (n)</cell><cell>53</cell><cell>83</cell><cell>301</cell><cell>302</cell></row><row><cell>HR (95% CI)</cell><cell>0.61 (0.43-0.87)</cell><cell></cell><cell>0.84 (0.72-0.99)</cell><cell></cell></row><row><cell>p value</cell><cell>0.006</cell><cell></cell><cell>0.03</cell><cell></cell></row><row><cell>Radiographic PFS</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median, mo (IQR)</cell><cell>27.6 (13.6-NR)</cell><cell>11.1 (3.7-21.8)</cell><cell>13.7 (7.4-27.7)</cell><cell>8.2 (3.5-16.6)</cell></row><row><cell>Number of events (n)</cell><cell>65</cell><cell>99</cell><cell>267</cell><cell>265</cell></row><row><cell>HR (95% CI)</cell><cell>0.41 (0.30-0.57)</cell><cell></cell><cell>0.59 (0.50-0.70)</cell><cell></cell></row><row><cell>p value</cell><cell>&lt;0.001</cell><cell></cell><cell>&lt;0.001</cell><cell></cell></row><row><cell>Time to chemotherapy use</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median, mo (IQR)</cell><cell>37.0 (18.3-54.7)</cell><cell>24.3 (11.7-NR)</cell><cell>23.3 (12.5-48.2)</cell><cell>14.5 (8-39.2)</cell></row><row><cell>Number of events (n)</cell><cell>65</cell><cell>82</cell><cell>256</cell><cell>264</cell></row><row><cell>HR (95% CI)</cell><cell>0.64 (0.46-0.89)</cell><cell></cell><cell>0.71 (0.60-0.85)</cell><cell></cell></row><row><cell>p value</cell><cell>0.007</cell><cell></cell><cell>&lt; 0.001</cell><cell></cell></row><row><cell>Time to opiate use</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median, mo (IQR)</cell><cell>NR (22.9-NR)</cell><cell>41.0 (18.2-NR)</cell><cell>30.5 (13.5-NR)</cell><cell>19.3 (10.6-46)</cell></row><row><cell>Number of events (n)</cell><cell>53</cell><cell>73</cell><cell>225</cell><cell>249</cell></row><row><cell>HR (95% CI)</cell><cell>0.69 (0.48-0.99)</cell><cell></cell><cell>0.70 (0.59-0.84)</cell><cell></cell></row><row><cell>p value</cell><cell>0.04</cell><cell></cell><cell>0.0001</cell><cell></cell></row><row><cell>Treatment duration</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median, mo</cell><cell>20.4</cell><cell>11.2</cell><cell>12.3</cell><cell>7.2</cell></row><row><cell>HR (95% CI)</cell><cell>0.41 (0.31-0.54)</cell><cell></cell><cell>0.54 (0.46-0.62)</cell><cell></cell></row><row><cell>p value</cell><cell>&lt;0.001</cell><cell></cell><cell>&lt;0.001</cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgments: The authors would like to thank Laurent Antoni (Janssen EMEA) for assistance with reviewing of the manuscript.</s><s>Writing assistance was provided by Natalie Dennis from PAREXEL, which was funded by Janssen EMEA.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Funding/Support and role of the sponsor: This analysis was funded by Janssen EMEA, which was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Kurt Miller has received consultancy fees from Amgen</title>
		<imprint>
			<pubPlace>Astellas, Bayer, Bristol-Myers Squibb, Ferring, Janssen, Medivation, Merck, Merck Sharp &amp; Dohme, Pfizer, and</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><surname>Roche</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">Gschwend has received consulting and lecturing fees from Astellas</title>
		<author>
			<persName><surname>Bayer</surname></persName>
		</author>
		<author>
			<persName><surname>From Amgen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bristol-Myers</forename><surname>Astellas</surname></persName>
		</author>
		<author>
			<persName><surname>Squibb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanofi</forename><surname>Pfizer</surname></persName>
		</author>
		<author>
			<persName><surname>Jürgen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Janssen</forename><surname>Bayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Roche</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Hendrik Van Poppel has no financial disclosures. Joris Diels is an employee of Janssen</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Brookman-May is an employee of, and shareholder at</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sabine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Janssen. References</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Aziz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kempkensteffen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>May</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Anticancer Ther</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="649" to="666" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The changing therapeutic landscape of castration-resistant prostate cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Yap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zivi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Omlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>De Bono</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="597" to="610" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Provenge: withdrawal of the marketing authorisation in the European Union</title>
	</analytic>
	<monogr>
		<title level="j">European Medicines Agency. Public statement</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Halabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Kelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="671" to="677" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Abiraterone in metastatic prostate cancer without previous chemotherapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>De Bono</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="138" to="148" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fizazi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="152" to="160" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Scher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Halabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tannock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1148" to="1159" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kheoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>with abiraterone acetate (AA) [abstract</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">5047</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Enzalutamide in metastatic prostate cancer before chemotherapy</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Beer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Rathkopf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="424" to="433" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Garrett-Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>De Wit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">F</forename><surname>Tannock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eisenberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="6396" to="6403" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Pain predicts overall survival in men with metastatic castration-refractory prostate cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Halabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Vogelzang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Kornblith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2544" to="2549" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review</title>
		<author>
			<persName><forename type="first">G</forename><surname>Colloca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Venturino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Checcaglini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Treat Rev</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="501" to="506" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The prognostic significance of patient-reported outcomes in cancer clinical trials</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Gotay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Kawamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bottomley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Efficace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1355" to="1363" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Sourbeer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Genitourin Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="60" to="66" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Schellhammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chodak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Whitmore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sims</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Frohlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Kantoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="1297" to="1302" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Londhe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Molina</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>abstract</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">5010</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>Saad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De Bono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="223" to="230" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Predictors of long-term response to abiraterone in patients with metastatic castrationresistant prostate cancer: a retrospective cohort study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Verzoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Giorgi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Derosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="40085" to="40094" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Correlation between prostatespecific antigen kinetics and overall survival in abiraterone acetatetreated castration-resistant prostate cancer patients</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">S</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stuyckens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3170" to="3177" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France</title>
		<author>
			<persName><forename type="first">N</forename><surname>Houede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Beuzeboc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gourgou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">222</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Early prediction of therapy response to abiraterone acetate using PSA subforms in patients with castration resistant prostate cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schlack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Krabbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fobker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Schrader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Semjonow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boegemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">1520</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nakabayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Taplin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="2990" to="2998" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">Concordance of the Gleason score in prostate multibiopsy and definitive histology</title>
		<author>
			<persName><forename type="first">M</forename><surname>May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Brookman-May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lebentrau</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Aktuelle Urol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="184" to="192" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Brookman-May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Wieland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Urol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="97" to="103" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">A UK-based investigation of interand intra-observer reproducibility of Gleason grading of prostatic biopsies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Melia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Moseley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Ball</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="644" to="654" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fizazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Flaig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stockle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="699" to="705" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title/>
		<author>
			<persName><surname>E U R O P E A N U R O L O G Y 74</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page" from="17" to="19" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
